Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Trevi Therapeutics Inc

Healthcare US TRVI

13.33USD
-0.6(4.31%)

Last update at 2026-06-05T20:00:00Z

Day Range

13.3113.93
LowHigh

52 Week Range

0.974.00
LowHigh

Fundamentals

  • Previous Close 13.93
  • Market Cap180.31M
  • Volume729270
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-38.12700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.18800M -33.96100M -32.77600M -26.06800M -20.66900M
Minority interest - - - - 0.00000M
Net income -29.15200M -33.94000M -32.75800M -26.05000M -20.54500M
Selling general administrative 10.07M 9.49M 10.16M 7.31M 4.34M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.04M 0.05M 0.05M 0.04M 0.02M
Ebit -29.95000M -32.47600M -32.53600M -26.68400M -20.49500M
Ebitda -29.90700M -32.79100M -32.48900M -26.64500M -20.47200M
Depreciation and amortization 0.04M -0.31500M 0.05M 0.04M 0.02M
Non operating income net other 0.14M - -0.00900M - -
Operating income -29.90700M -32.47600M -32.48900M -26.64500M -18.40800M
Other operating expenses 29.91M 32.48M 32.49M 26.64M 18.41M
Interest expense 0.78M 1.20M 0.46M 0.62M 0.17M
Tax provision -0.03600M -0.02100M -0.01800M -0.01800M -0.12400M
Interest income 1.74M 0.01000M 0.18M 0.79M 0.16M
Net interest income 0.58M -1.19200M -0.27800M 0.79M -0.01800M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.03600M -0.02100M -0.01800M -0.01800M -0.12400M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 29.91M 32.48M 32.49M 26.64M 18.41M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.72M -1.48500M -0.28700M 0.58M -2.24300M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -29.15200M -33.94000M -32.75800M -26.05000M -20.54500M
Net income applicable to common shares -29.15200M -33.94000M -32.75800M -26.75400M -25.57700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 89.40M 123.02M 38.48M 47.13M 60.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.58M 1.31M 0.89M 0.11M 0.08M
Total liab 6.86M 15.56M 21.40M 19.85M 5.46M
Total stockholder equity 82.55M 107.46M 17.07M 27.28M 54.55M
Deferred long term liab - - - 0.28M -
Other current liab 3.71M 3.52M 0.11M 3.43M 3.50M
Common stock 0.07M 0.06M 0.03M 0.02M 0.02M
Capital stock 0.07M 0.06M 0.03M 0.02M 0.02M
Retained earnings -239.13400M -210.06900M -180.91700M -146.97700M -114.21900M
Other liab - 0.00300M - 0.20M -
Good will - - - - -
Other assets 0.00000M 0.20M 0.33M 0.00076M 0.02M
Cash 32.40M 12.59M 36.83M 45.00M 57.31M
Cash and equivalents - - - - -
Total current liabilities 5.82M 13.40M 12.72M 5.55M 5.20M
Current deferred revenue - - 3.81M - -
Net debt -31.05900M -3.41100M -22.20100M -30.79000M -56.95700M
Short term debt 0.31M 7.03M 5.95M 0.11M 0.10M
Short long term debt - 7.00M 5.83M - -
Short long term debt total 1.34M 9.18M 14.63M 14.21M 0.36M
Other stockholder equity 321.64M 317.59M 197.96M 174.24M 168.75M
Property plant equipment - 0.17M 0.18M 0.33M 0.43M
Total current assets 87.55M 122.62M 37.96M 46.27M 59.55M
Long term investments - - - - -
Net tangible assets - 107.46M 17.07M 27.28M 54.55M
Short term investments 50.57M 107.92M - - -
Net receivables - - 0.24M 0.27M 0.56M
Long term debt - 2.15M 8.65M 13.95M -
Inventory - - -0.24100M 0.90M 1.60M
Accounts payable 1.81M 2.86M 2.85M 2.02M 1.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.02900M -0.12200M - - -60.00100M
Additional paid in capital - - - - -
Common stock total equity - 0.06M - 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - -210.06900M - -146.97700M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.20M 0.33M 0.53M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 1.86M 0.40M 0.52M 0.86M 0.45M
Capital lease obligations 1.34M 0.03M 0.14M 0.26M 0.36M
Long term debt total - 2.15M - 14.15M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -126.21500M -107.21400M -0.03200M -0.00900M -0.15800M
Change to liabilities -0.63000M 0.83M 0.42M 0.78M 0.07M
Total cashflows from investing activities -107.37300M -107.37300M -0.03200M -0.00900M -0.15800M
Net borrowings -5.85400M -5.83300M 14.00M 14.00M -4.81300M
Total cash from financing activities 111.31M 20.77M 16.72M 73.21M 3.63M
Change to operating activities -1.24000M 0.68M 0.35M 1.17M -0.49700M
Net income -29.15200M -33.94000M -32.75800M -26.05000M -20.54500M
Change in cash -24.24100M -8.17100M -12.31200M 50.11M -14.81800M
Begin period cash flow 36.83M 45.00M 57.31M 7.20M 22.02M
End period cash flow 12.59M 36.83M 45.00M 57.31M 7.20M
Total cash from operating activities -28.17500M -28.94600M -29.00000M -23.09300M -18.29100M
Issuance of capital stock 105.41M 21.18M 3.13M 75.06M 10.50M
Depreciation 0.04M 0.05M 0.05M 0.04M 0.02M
Other cashflows from investing activities 19.00M - - - 0.00000M
Dividends paid - - - -2.23900M 0.00000M
Change to inventory - - -0.29300M 0.37M 0.00000M
Change to account receivables - - 0.29M -0.37400M -0.13500M
Sale purchase of stock 117.16M - -0.33100M -1.21300M 10.51M
Other cashflows from financing activities 11.73M -0.40800M 13.59M 13.80M 8.97M
Change to netincome 2.33M 2.84M 2.43M 1.34M 2.74M
Capital expenditures 0.16M 0.16M 0.03M 0.00900M 0.16M
Change receivables - - - - -
Cash flows other operating -0.45400M - 0.75M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -24.24100M - -12.31200M - -
Change in working capital -1.23100M 1.51M 1.06M 1.58M -0.56800M
Stock based compensation 2.33M 2.54M 2.42M 1.13M 0.50M
Other non cash items -0.16200M 0.97M 0.23M 0.21M 2.30M
Free cash flow -28.33400M -28.94600M -29.03200M -23.10200M -18.44900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TRVI
Trevi Therapeutics Inc		 -0.6 4.31% 13.33 - - - 2.44 -4.1889
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics Inc

195 Church Street, New Haven, CT, United States, 06510

Key Executives

Name Title Year Born
Ms. Jennifer L. Good Co-Founder, CEO, Pres & Director 1965
Dr. Thomas R. Sciascia M.D. Co-Founder & Chief Science Officer 1953
Ms. Lisa Delfini Chief Financial Officer 1970
Mr. Christopher Galletta Controller & Chief Accounting Officer 1978
Katie McManus Communications Mang. NA
Mr. Farrell Simon Pharm.D. Sr. VP and Head of Commercial & Strategy NA
Dr. David J. Clark A.F.P.M., M.D., M.R.C.P. Chief Medical Officer 1965
Ms. Danine Summers VP of Medical Affairs 1958
Ms. Jennifer L. Good Co-Founder, CEO, President & Director 1965
Katie McManus Communications Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions